Karyopharm Therapeutics is a clinical-stage pharmaceutical company, based in Newton, MA, USA, focused on the discovery, development and commercialization of novel, first-in-class agents targeting nuclear transport for the treatment of cancer and other major diseases.
Karyopharm is the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) technology, developed to address a central mechanism of oncogenesis via the inhibition of exportins, specifically XPO1. Selinexor, Karyopharm’s lead candidate, has been administered to patients with hematologic malignancies or solid tumors in clinical trials, worldwide. Karyopharm is currently preparing for its first potential U.S. commercial launch in 2019.
In addition to selinexor, Karyopharm is also advancing a pipeline of novel, oral drug candidates, including eltanexor as a treatment for myelodysplastic syndrome, colorectal cancer and castrate-resistant prostate cancer, verdinexor as an anti-viral agent, as well as a potential treatment for cancer in companion animals, and KPT-9274, a dual PAK4/NAMPT inhibitor for the treatment of patients with advanced solid malignancies or non-Hodgkin’s lymphoma.
Karyopharm was founded by Dr. Sharon Shacham and is headquartered in Newton, MA.
